Table 4.
Analysis of surgical treatment of women based on ESGO Clinical Risk Group assesment. SLN – sentinel lymph node biopsy, LND - lymphadenectomy
| ESGO integrated molecular risk | Total number of women | Open surgery | Laparoscopic | SLN | LND | Unilateral SNB and contralateral LND | No LN treatment |
|---|---|---|---|---|---|---|---|
| Low risk | 22 (56.4%) | 2 (5.1%) | 20 (51.3%) | 18 (46.2%) | 0 | 0 | 4 (10.3%) |
| Intermediate | 4 (10.3%) | 0 | 4 (10.3%) | 3 (7.7%) | 1 (2.6%) | 0 | 0 |
| HIR | 3 (7.7%) | 1 (2.6%) | 2 (5.1%) | 0 | 2 (5.1%) | 1 (2.6%) | 0 |
| High | 9 (23.1%) | 5 (12.8%) | 4 (10.3%) | 2 (5.1%) | 5 (12.8%) | 2 (5.1%) | 1 (2.6%) |
| Advanced | 1 (2.6%) | 1 (2.6%) | 0 | 0 | 0 | 0 | 1 (2.6%) |
HIR = high-intermediate risk; LND = lymphadenectomy; SLN = sentinel lymph node biopsy